Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Figures & data

Table 1. Characteristics of vitiligo participant visits.

	Number of vitiligo patients, n = 49 (%)
Sex
Female	30 (61%)
Male	19 (39%)
Race
White only	25 (51%)
Black/African American only	6 (12%)
Asian only	2 (4%)
Native Hawaiian/other Pacific islander only	0 (0%)
American Indian/Alaskan Native only	2 (4%)
More than one ethnicity	0 (0%)
Unknown*	14 (29%)
Ethnicity
Hispanic/Latino	9 (18%)
Not Hispanic/Latino	30 (61%)
Unknown*	9 (18%)
Age
Average age, range	22.7 years (1–85)
Number of pediatric patients (<18 years old), average age, range	17 (34.7%), 9.2 years (range 1-17 years)
Insurance status
Private insurance	26 (53%)
Medicare	8 (16%)
Medicaid or CHIP	6 (12%)
Self-pay	2 (4%)
Workers’ compensation	0 (0%)
No charge/charity	2 (4%)
Other	2 (4%)
Unknown*	4 (4%)
Subspeciality of provider
Dermatologist	19 (39%)
Non-dermatologist	19 (39%)
Unknown*	11 (22%)

Table Legend: CHIP = children’s health insurance program, * = number of responses left blank.

Figure 1. Percentage of visits that the medication was prescribed. Note: NAMCS = National Ambulatory Medical Care Survey.

Table 2. Distribution of medications prescribed for vitiligo patient visits.

Medication class, type of medication	Number of visits, n = 49 (%)
Number of medications
Average, range	2.2 (0–14)
Number of visits with no vitiligo medications	22
Topical corticosteroids	Total: 21 (43%)
Clobetasol	5 (10%)
Triamcinolone	5 (10%)
Desonide	4 (8%)
Fluocinonide	4 (8%)
Clocortolone	1 (2%)
Fluticasone	1 (2%)
Hydrocortisone	1 (2%)
Other topical agents	Total: 14 (29%)
Pimecrolimus	5 (10%)
Tacrolimus	5 (10%)
Calcipotriol	2 (8%)
Calcitriol	1 (2%)
Monobenzone	1 (2%)
Systemic agents	Total: 2 (4%)
Tacrolimus	1 (2%)
Tofacitinib	1 (2%)
Procedures	Total: 1 (2%)
Liquid nitrogen	1 (2%)
Pediatric subgroup analysis
N, number not receiving any vitiligo medications.	N = 17, 9 (53%)
Topical corticosteroids	Total: 7 (41%)
Desonide	2 (12%)
Clobetasol	1 (6%)
Fluocinonide	1 (6%)
Fluticasone	1 (6%)
Hydrocortisone	1 (6%)
Triamcinolone	1 (6%)
Other topical agents	Total: 5 (29%)
Pimecrolimus	2 (12%)
Tacrolimus	2 (12%)
Calcipotriene	1 (6%)

Data availability

All data sources utilized in this study are publicly available.